201 related articles for article (PubMed ID: 35471711)
1. Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Goeree R; Burke N; Jobin M; Brown JP; Lawrence D; Stollenwerk B; Willems D; Johnson B
Arch Osteoporos; 2022 Apr; 17(1):71. PubMed ID: 35471711
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
Gielen E; Aldvén M; Kanis JA; Borgström F; Senior E; Willems D
Osteoporos Int; 2024 Jul; 35(7):1173-1183. PubMed ID: 38565690
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.
Söreskog E; Lindberg I; Kanis JA; Åkesson KE; Willems D; Lorentzon M; Ström O; Berling P; Borgström F
Osteoporos Int; 2021 Mar; 32(3):585-594. PubMed ID: 33409591
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
Hagino H; Tanaka K; Silverman S; McClung M; Gandra SR; Charokopou M; Adachi K; Johnson B; Stollenwerk B
Osteoporos Int; 2021 Oct; 32(10):2011-2021. PubMed ID: 33772328
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
9. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Tian L; Luo C; Li YF; Wang QY; Qu XL; Yue C; Xu LL; Yang YY; Sheng ZF
Arch Osteoporos; 2023 Jul; 18(1):100. PubMed ID: 37460858
[TBL] [Abstract][Full Text] [Related]
11. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
12. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
13. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
15. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Berto P; Maggi S; Noale M; Lopatriello S
Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
[TBL] [Abstract][Full Text] [Related]
17. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]